# Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy

> **NCT00283062** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 228 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** Docetaxel (TAXOTERE®) Chemotherapy
- **DRUG:** Leuprolide acetate ( ELIGARD®) Hormonal Therapy
- **DRUG:** Docetaxel (TAXOTERE®) Chemotherapy
- **DRUG:** Leuprolide acetate ( ELIGARD®) Hormonal Therapy
- **DRUG:** Leuprolide acetate ( ELIGARD®) Hormonal Therapy

## Key facts

- **NCT ID:** NCT00283062
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 228 (ACTUAL)
- **Last updated:** 2012-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00283062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00283062, "Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00283062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*